Polycystic Ovarian Syndrome Therapeutics Market - Forecast(2024 - 2030)

The Polycystic Ovarian Syndrome Therapeutics Market size is estimated to reach $6.3 billion by 2028, growing at a CAGR of 4.9% during the forecast period 2023-2028. Polycystic ovary syndrome (PCOS) is a complicated condition characterized by high androgen levels, menstrual inconsistencies and/or small cysts on one or both ovaries. PCOS is connected with an excess of cardio-metabolic results. A number of women enduring polycystic ovary syndrome may be recommended antidepressants to rectify the impacts of depression. Anti-obesity agents that have been investigated in PCOS involve orlistat, sibutramine and rimonabant. Currently, 1 out of 10 women has PCOS, which is a hormonal imbalance bringing about irregular periods, unwanted hair growth and acne. The 5-year complete survival with long-term androgen suppression therapy or androgen deprivation therapy (ADT) was 95% in comparison with 86% in the short-term group. Investigations have been conducted where men were on intermittent peripheral blockade for a median of 20.2 months. The distinct technical progress involving androgen suppressors and peripheral androgen blockers is set to propel the growth of the Polycystic Ovarian Syndrome Therapeutics Industry during the forecast period 2023-2028. This represents the Polycystic Ovarian Syndrome Therapeutics Industry Outlook.

Polycystic Ovarian Syndrome Therapeutics Market Report Coverage

The “Polycystic Ovarian Syndrome Therapeutics Market Report - Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Polycystic Ovarian Syndrome Therapeutics Market.

By Drug Class: Oral Contraceptives, Antiandrogens, Insulin Sensitizing Agent, Antidepressant, Anti-obesity and Others.
By Surgery: Ovarian Wedge Resection, Laparoscopic Ovarian Drilling and Others.
By Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

• Geographically, North America (Polycystic Ovarian Syndrome Therapeutics market share) accounted for the highest revenue share in 2022 and it is poised to dominate the market over the period 2023-2028 due to soaring awareness of polycystic ovary syndrome in the North American region.
• The growth of the Polycystic Ovarian Syndrome Therapeutics Market is being driven by rising sedentary lifestyles and family dietary habits, resulting in increasing cases of polycystic ovary syndrome. However, side effects of symptomatic treatment drugs and the dearth of approved drugs directly targeting PCOS ailment are some of the major factors hampering the growth of the Polycystic Ovarian Syndrome Therapeutics Market.
• The Polycystic Ovarian Syndrome Therapeutics Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Polycystic Ovarian Syndrome Therapeutics Market report. 

Polycystic Ovarian Syndrome Therapeutics Market Segment Analysis - by Drug Class

The Polycystic Ovarian Syndrome Therapeutics Market based on drug class can be further segmented into Oral Contraceptives, Antiandrogens, Insulin Sensitizing agents, Antidepressants, Anti-obesity and Others. The Oral Contraceptives Segment held the largest share of the Polycystic Ovarian Syndrome Therapeutics market in 2022. This growth is fueled by the surging application of oral contraceptive pills for the regulation of the menstrual cycle in young women with PCOS. Girls consuming oral contraceptive pills are less inclined to be anemic. The capability of oral contraceptive pills to reduce menstrual cramps is further propelling the growth of the Oral Contraceptives segment. Furthermore, the Antiandrogens segment is estimated to grow at the fastest CAGR of 5.3% during the forecast period 2023-2028 due to antiandrogens, combined with ovarian suppression providing the best hope for improvement of hirsutism and androgenetic alopecia in women with PCOS.

Polycystic Ovarian Syndrome Therapeutics Market Segment Analysis - by Surgery

The Polycystic Ovarian Syndrome Therapeutics Market based on surgery can be further segmented into Ovarian Wedge Resection, Laparoscopic Ovarian Drilling and Others. The Laparoscopic Ovarian Drilling Segment held the largest share of the Polycystic Ovarian Syndrome Therapeutics market in 2022. This growth is fueled by the surging application of Laparoscopic Ovarian Drilling surgery in crucial conditions. This surgery is carried out because of prevalent fertility issues in women with PCOS and declining response to medicines over time. The increasing inclination towards Laparoscopic Ovarian Drilling due to its high success rate in women as per investigations is further propelling the growth of this segment. Furthermore, the Laparoscopic Ovarian Drilling segment is estimated to grow at the fastest CAGR of 5.5% during the forecast period 2023-2028 due to the increasing inclination of patients towards Laparoscopic Ovarian Drilling attributed to its cost-effectiveness.

Polycystic Ovarian Syndrome Therapeutics Market Segment Analysis - by Geography

North America (Polycystic Ovarian Syndrome Therapeutics Market) dominated the largest Polycystic Ovarian Syndrome Therapeutics market with a 37% share of the overall market in 2022. The growth of this region is driven by the increasing predominance of obesity in the North American region. The increasing count of novel cases of polycystic ovary syndrome is further propelling the growth of the Polycystic Ovarian Syndrome Therapeutics Industry, thereby contributing to the Polycystic Ovarian Syndrome Therapeutics Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. The growing acceptance of PCOS treatment products is further fueling the progress of the Polycystic Ovarian Syndrome Therapeutics Market in the Asia-Pacific region.

Polycystic Ovarian Syndrome Therapeutics Market Drivers

Vital Role of Anti-obesity Agents in Polycystic Ovary Syndrome:

Insulin resistance is recorded in clamp investigations in 75% of women with polycystic ovary syndrome. The role of anti-obesity pharmacological agents in accomplishing and sustaining weight loss is being increasingly acknowledged. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) not only serve by decreasing body weight but also can influence the mechanisms included in insulin resistance, like increasing expression of glucose transporters in insulin-dependent tissues, reducing inflammation, decreasing oxidative stress and harmonizing lipid metabolism. They also are inclined to enhance fertility. The major role of anti-obesity agents in polycystic ovary syndrome is therefore fueling the growth of the Polycystic Ovarian Syndrome Therapeutics Market during the forecast period 2023-2028.

Increasing Applications of Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclics:

Investigations indicate that anywhere from 27% to about 50% of women with polycystic ovary syndrome record depression in comparison with 19% of women without PCOS. Numerous physicians recommend antidepressants like selective serotonin reuptake inhibitors (SSRIs) due to their fewer side effects and they are thought typically safe to consume when compared with other alternatives. They can relieve depression that is categorized from moderate to severe. Tricyclics are antidepressants that perform by obstructing the reuptake of serotonin and norepinephrine. SSRIs aim at serotonin only. 

Polycystic Ovarian Syndrome Therapeutics Market Challenge

Misdiagnosis of Lean Women with Polycystic Ovary Syndrome (PCOS):

Lean polycystic ovary syndrome (PCOS) is related to people with normal weight. Around 30% of women with the condition fall into this class. Since polycystic ovary syndrome is mostly linked to obesity, lean women with PCOS are repeatedly misdiagnosed for years. Lean women with PCOS may not be diagnosed until they are not able to conceive. Not only PCOS diagnosis is deferred, but diagnosis of diabetes and heart disease may also be deferred in lean women with PCOS. These issues are thus hampering the growth of the Polycystic Ovarian Syndrome Therapeutics Market.

Polycystic Ovarian Syndrome Therapeutics Industry Outlook

Focus on symptomatic treatments, drugs in clinical trials and not approved for marketing, increasing focus on surgeries and numerous medical devices focused on surgeries are key strategies adopted by players in the Polycystic Ovarian Syndrome Therapeutics Market. The top 10 companies in the Polycystic Ovarian Syndrome Therapeutics market include:

1. Reliance Life Sciences Private Limited
2. Merck KGaA
3. Crinetics Pharmaceuticals, Inc.
4. Ferring Pharmaceuticals, Inc.
5. Neurocrine Biosciences, Inc.
6. AstraZeneca plc.
7. Abbott
8. Sanofi S.A.
9. Pfizer, Inc.
10. Novartis AG

Recent Developments

• In July 2021, AstraZeneca finished the acquisition of Alexion Pharmaceuticals, Inc. The conclusion of the acquisition indicates the Firm’s entry into medications for unique ailments. Presently, AstraZeneca has improved its scientific existence in immunology.
• In April 2021, Merck declared a favorable finish of a cash tender offer, through a subsidiary. This was for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. This was performed at the purchase price of $60 per share.
• In June 2020, Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Company Limited declared a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Particularly, Takeda granted an exclusive license to Neurocrine Biosciences. This was performed for seven pipeline programs. 

Relevant Reports:

Short Bowel Syndrome Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0954

Muckle-Wells Syndrome Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0294

Cancer Hormone Therapy Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0196

For more Lifesciences and Healthcare Market reports, please click here